Palifermin
( DrugBank: Palifermin / KEGG DRUG: Palifermin )
6 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis | 2 |
| 36 | Epidermolysis bullosa | 1 |
| 38 | Stevens-Johnson syndrome | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 39 | Toxic epidermal necrolysis | 1 |
| 65 | Primary immunodeficiency | 4 |
| 96 | Crohn disease | 1 |
13. Multiple sclerosis
Clinical trials : 3,685 / Drugs : 1,932 - (DrugBank : 355) / Drug target genes : 263 - Drug target pathways : 237
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
36. Epidermolysis bullosa
Clinical trials : 183 / Drugs : 159 - (DrugBank : 51) / Drug target genes : 69 - Drug target pathways : 147
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
38. Stevens-Johnson syndrome
Clinical trials : 19 / Drugs : 25 - (DrugBank : 10) / Drug target genes : 14 - Drug target pathways : 98
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
39. Toxic epidermal necrolysis
Clinical trials : 15 / Drugs : 16 - (DrugBank : 9) / Drug target genes : 10 - Drug target pathways : 99
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
65. Primary immunodeficiency
Clinical trials : 798 / Drugs : 585 - (DrugBank : 118) / Drug target genes : 100 - Drug target pathways : 216
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
96. Crohn disease
Clinical trials : 2,737 / Drugs : 1,197 - (DrugBank : 240) / Drug target genes : 182 - Drug target pathways : 221
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|